The impact of the bone marrow microenvironment on multiple myeloma (Review)

Hou,Jianhao; Wei,Rongfang; Qian,Jinjun; Wang,Ronggen; Fan,Zhimin; Gu,Chunyan; Yang,Ye

doi:10.3892/or.2019.7261

The impact of the bone marrow microenvironment on multiple myeloma (Review)

Authors:
- Jianhao Hou
- Rongfang Wei
- Jinjun Qian
- Ronggen Wang
- Zhimin Fan
- Chunyan Gu
- Ye Yang
View Affiliations

Affiliations: National Medical Centre of Colorectal Disease, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210001, P.R. China, School of Medicine and Life Sciences, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China
Published online on: August 5, 2019 https://doi.org/10.3892/or.2019.7261
Pages: 1272-1282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) is characterized by the accumulation of monoclonal plasma cells in the bone marrow (BM). The interaction between the BM microenvironment and MM plasma cells can influence cell proliferation, drug resistance and prognosis of the disease. The BM microenvironment (BMME) consists of a cellular and non‑cellular compartment. The cellular compartment includes stromal cells, endothelial cells, osteoclasts and osteoblasts, and the non‑cellular compartment includes the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors and chemokines. The complex interaction between the BM microenvironment and MM plasma cells influences disease development and prognosis. The present review focuses on the interaction between malignant plasma cells and the BM microenvironment during MM progression. An improved understanding of the interaction between MM plasma cells and their microenvironment will enable the development of novel therapeutic tools that can be used in the treatment of MM, a currently incurable blood cancer.

View Figures

View References

1	Rajkumar SV: Myeloma today: Disease definitions and treatment advances. Am J Hematol. 91:90–100. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
3	Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, et al: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 113:5412–5417. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, et al: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 24:1121–1127. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kunisaki Y, Bruns I, Scheiermann C, Ahmed J, Pinho S, Zhang D, Mizoguchi T, Wei Q, Lucas D, Ito K, et al: Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 502:637–643. 2013. View Article : Google Scholar : PubMed/NCBI
6	Manier S, Sacco A, Leleu X, Ghobrial IM and Roccaro AM: Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012:1574962012. View Article : Google Scholar : PubMed/NCBI
7	Crisan M and Dzierzak E: The many faces of hematopoietic stem cell heterogeneity. Development. 143:4571–4581. 2016. View Article : Google Scholar : PubMed/NCBI
8	Pang WW, Schrier SL and Weissman IL: Age-associated changes in human hematopoietic stem cells. Semin Hematol. 54:39–42. 2017. View Article : Google Scholar : PubMed/NCBI
9	Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121:1298–1312. 2011. View Article : Google Scholar : PubMed/NCBI
10	Corcoran KE, Patel N and Rameshwar P: Stromal derived growth factor-1alpha: Another mediator in neural-emerging immune system through Tac1 expression in bone marrow stromal cells. J Immunol. 178:2075–2082. 2007. View Article : Google Scholar : PubMed/NCBI
11	Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ and Taichman RS: GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 12:116–127. 2010. View Article : Google Scholar : PubMed/NCBI
12	Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD and Cher ML: CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate. 66:32–48. 2006. View Article : Google Scholar : PubMed/NCBI
13	Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC and Ghobrial IM: Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 263:160–172. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ribatti D, Nico B and Vacca A: Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 25:4257–4266. 2006. View Article : Google Scholar : PubMed/NCBI
15	Ghobrial IM: Myeloma as a model for the process of metastasis: Implications for therapy. Blood. 120:20–30. 2012. View Article : Google Scholar : PubMed/NCBI
16	Anderson KC and Carrasco RD: Pathogenesis of myeloma. Annu Rev Pathol. 6:249–274. 2011. View Article : Google Scholar : PubMed/NCBI
17	Abdi J, Chen G and Chang H: Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget. 4:2186–2207. 2013. View Article : Google Scholar : PubMed/NCBI
18	Bianchi G and Munshi NC: Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 125:3049–3058. 2015. View Article : Google Scholar : PubMed/NCBI
19	Ribatti D, Moschetta M and Vacca A: Microenvironment and multiple myeloma spread. Thromb Res. 133 (Suppl 2):S102–S106. 2014. View Article : Google Scholar : PubMed/NCBI
20	Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E and Vanderkerken K: The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res. 110:19–42. 2011. View Article : Google Scholar : PubMed/NCBI
21	Wu Q, Zhou X, Huang D, Ji Y and Kang F: IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cell Physiol Biochem. 41:1360–1369. 2017. View Article : Google Scholar : PubMed/NCBI
22	Hideshima T, Chauhan D, Schlossman R, Richardson P and Anderson KC: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene. 20:4519–4527. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K and Menu E: Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 124:555–566. 2014. View Article : Google Scholar : PubMed/NCBI
24	Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, et al: BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 123:1542–1555. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A and Menu E: Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 239:162–173. 2016. View Article : Google Scholar : PubMed/NCBI
26	Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Wellik LA, Fonseca R, Lust JA, Witzig TE, Kyle RA, Greipp PR and Rajkumar SV: Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant. 34:235–239. 2004. View Article : Google Scholar : PubMed/NCBI
27	Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, et al: Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia. 30:1103–1115. 2016. View Article : Google Scholar : PubMed/NCBI
28	Vacca A and Ribatti D: Angiogenesis and vasculogenesis in multiple myeloma: Role of inflammatory cells. Recent Results Cancer Res. 183:87–95. 2011. View Article : Google Scholar : PubMed/NCBI
29	Andreuzzi E, Colladel R, Pellicani R, Tarticchio G, Cannizzaro R, Spessotto P, Bussolati B, Brossa A, De Paoli P, Canzonieri V, et al: The angiostatic molecule Multimerin 2 is processed by MMP-9 to allow sprouting angiogenesis. Matrix Biol. 64:40–53. 2017. View Article : Google Scholar : PubMed/NCBI
30	Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M and Vacca A: Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res. 1:76–89. 2011.PubMed/NCBI
31	Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F and Dammacco F: A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 88:176–185. 2003.PubMed/NCBI
32	Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B and Vanderkerken K: Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: Study in the 5T33MM model. Br J Cancer. 90:1076–1083. 2004. View Article : Google Scholar : PubMed/NCBI
33	Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, et al: Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res. 13:816–823. 2007. View Article : Google Scholar : PubMed/NCBI
34	Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC and Roodman GD: Osteoclasts are important for bone angiogenesis. Blood. 115:140–149. 2010. View Article : Google Scholar : PubMed/NCBI
35	Hideshima T, Mitsiades C, Tonon G, Richardson PG and Anderson KC: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
36	Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, et al: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66:184–191. 2006. View Article : Google Scholar : PubMed/NCBI
37	Bonewald LF: The amazing osteocyte. J Bone Miner Res. 26:229–238. 2011. View Article : Google Scholar : PubMed/NCBI
38	Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P and Alexandre C: Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol. 7:1909–1914. 1989. View Article : Google Scholar : PubMed/NCBI
39	Delgado-Calle J, Bellido T and Roodman GD: Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care. 8:407–413. 2014. View Article : Google Scholar : PubMed/NCBI
40	Kristensen IB, Christensen JH, Lyng MB, Møller MB, Pedersen L, Rasmussen LM, Ditzel HJ and Abildgaard N: Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: Only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma. 55:911–919. 2014. View Article : Google Scholar : PubMed/NCBI
41	Walker RE, Lawson MA, Buckle CH, Snowden JA and Chantry AD: Myeloma bone disease: Pathogenesis, current treatments and future targets. Br Med Bull. 111:117–138. 2014. View Article : Google Scholar : PubMed/NCBI
42	Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, et al: Increased osteocyte death in multiple myeloma patients: Role in myeloma-induced osteoclast formation. Leukemia. 26:1391–1401. 2012. View Article : Google Scholar : PubMed/NCBI
43	Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD and Giuliani N: IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 106:1407–1414. 2005. View Article : Google Scholar : PubMed/NCBI
44	Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD and Choi SJ: IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 103:2308–2315. 2004. View Article : Google Scholar : PubMed/NCBI
45	Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, et al: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood. 104:2484–2491. 2004. View Article : Google Scholar : PubMed/NCBI
46	Croucher PI, McDonald MM and Martin TJ: Bone metastasis: The importance of the neighbourhood. Nat Rev Cancer. 16:373–386. 2016. View Article : Google Scholar : PubMed/NCBI
47	Ehrlich LA and Roodman GD: The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma. Immunol Rev. 208:252–266. 2005. View Article : Google Scholar : PubMed/NCBI
48	Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 273:14363–14367. 1998. View Article : Google Scholar : PubMed/NCBI
49	Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R and Croucher PI: An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res. 67:202–208. 2007. View Article : Google Scholar : PubMed/NCBI
50	Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, et al: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6:89832015. View Article : Google Scholar : PubMed/NCBI
51	McDonald MM, Fairfield H, Falank C and Reagan MR: Adipose, bone, and myeloma: Contributions from the microenvironment. Calcif Tissue Int. 100:433–448. 2017. View Article : Google Scholar : PubMed/NCBI
52	Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, Ruan E, Wang G, Wang H, Song J and Shao Z: Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int. 14:1322014. View Article : Google Scholar : PubMed/NCBI
53	Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M and Terpos E: Dickkopf-1: A suitable target for the management of myeloma bone disease. Expert Opin Ther Targets. 13:839–848. 2009. View Article : Google Scholar : PubMed/NCBI
54	Moester MJ, Papapoulos SE, Löwik CW and van Bezooijen RL: Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int. 87:99–107. 2010. View Article : Google Scholar : PubMed/NCBI
55	Zhou F, Meng S, Song H and Claret FX: Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention. Blood Rev. 27:261–267. 2013. View Article : Google Scholar : PubMed/NCBI
56	Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, et al: Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 106:3160–3165. 2005. View Article : Google Scholar : PubMed/NCBI
57	Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD and Bellido T: Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 76:1089–1100. 2016. View Article : Google Scholar : PubMed/NCBI
58	Reagan MR, Liaw L, Rosen CJ and Ghobrial IM: Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. Bone. 75:161–169. 2015. View Article : Google Scholar : PubMed/NCBI
59	Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G and Epstein J: Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 91:192–199. 2006.PubMed/NCBI
60	Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC and Anderson KC: The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 21:1007–1034, vii-viii. 2007. View Article : Google Scholar : PubMed/NCBI
61	Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63:912–916. 2003.PubMed/NCBI
62	Scheller J and Rose-John S: Interleukin-6 and its receptor: From bench to bedside. Med Microbiol Immunol. 195:173–183. 2006. View Article : Google Scholar : PubMed/NCBI
63	Suchi K, Fujiwara H, Okamura S, Okamura H, Umehara S, Todo M, Furutani A, Yoneda M, Shiozaki A, Kubota T, et al: Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res. 31:67–75. 2011.PubMed/NCBI
64	Hong DS, Angelo LS and Kurzrock R: Interleukin-6 and its receptor in cancer: Implications for translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
65	Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332:83–85. 1988. View Article : Google Scholar : PubMed/NCBI
66	Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC III, Waldschmidt TJ and Janz S: The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. Leukemia. 29:233–237. 2015. View Article : Google Scholar : PubMed/NCBI
67	Matthes T, Manfroi B, Zeller A, Dunand-Sauthier I, Bogen B and Huard B: Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia. 29:1882–1890. 2015. View Article : Google Scholar : PubMed/NCBI
68	Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F and Janz S: Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 59:188–202. 2014. View Article : Google Scholar : PubMed/NCBI
69	Qi C, Tian S, Wang J, Ma H, Qian K and Zhang X: Co-expression of CD40/CD40L on XG1 multiple myeloma cells promotes IL-6 autocrine function. Cancer Invest. 33:6–15. 2015. View Article : Google Scholar : PubMed/NCBI
70	Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA and Jelinek DF: CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 152:117–128. 1994.PubMed/NCBI
71	Dinarello CA: Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720–3732. 2011. View Article : Google Scholar : PubMed/NCBI
72	Tu Y, Gardner A and Lichtenstein A: The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: Roles in cytokine-dependent survival and proliferative responses. Cancer Res. 60:6763–6770. 2000.PubMed/NCBI
73	Hideshima T, Nakamura N, Chauhan D and Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 20:5991–6000. 2001. View Article : Google Scholar : PubMed/NCBI
74	Hsu JH, Shi Y, Hu L, Fisher M, Franke TF and Lichtenstein A: Role of the AKT kinase in expansion of multiple myeloma clones: Effects on cytokine-dependent proliferative and survival responses. Oncogene. 21:1391–1400. 2002. View Article : Google Scholar : PubMed/NCBI
75	Sansone P and Bromberg J: Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 30:1005–1014. 2012. View Article : Google Scholar : PubMed/NCBI
76	Matthes T, Manfroi B and Huard B: Revisiting IL-6 antagonism in multiple myeloma. Crit Rev Oncol Hematol. 105:1–4. 2016. View Article : Google Scholar : PubMed/NCBI
77	Monaghan KA, Khong T, Burns CJ and Spencer A: The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 25:1891–1899. 2011. View Article : Google Scholar : PubMed/NCBI
78	Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW and Anderson KC: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 89:227–234. 1997.PubMed/NCBI
79	Burger R: Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother. 40:336–343. 2013. View Article : Google Scholar : PubMed/NCBI
80	Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špička I, et al: A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol. 90:42–49. 2015. View Article : Google Scholar : PubMed/NCBI
81	San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, et al: Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 123:4136–4142. 2014. View Article : Google Scholar : PubMed/NCBI
82	Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, et al: A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol. 161:357–366. 2013. View Article : Google Scholar : PubMed/NCBI
83	Guo DJ, Han JS, Li YS, Liu ZS, Lu SY and Ren HL: In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma. Oncol Lett. 4:311–318. 2012. View Article : Google Scholar : PubMed/NCBI
84	Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, et al: Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 30:4161–4167. 2012. View Article : Google Scholar : PubMed/NCBI
85	Garcia-Bates TM, Bernstein SH and Phipps RP: Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin Cancer Res. 14:6414–6425. 2008. View Article : Google Scholar : PubMed/NCBI
86	Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, et al: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 113:4614–4626. 2009. View Article : Google Scholar : PubMed/NCBI
87	Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, et al: The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
88	Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, et al: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 5:221–230. 2004. View Article : Google Scholar : PubMed/NCBI
89	Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, et al: The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget. 5:11193–11208. 2014. View Article : Google Scholar : PubMed/NCBI
90	Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, et al: Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 120:3260–3270. 2012. View Article : Google Scholar : PubMed/NCBI
91	Bieghs L, Brohus M, Kristensen IB, Abildgaard N, Bøgsted M, Johnsen HE, Conover CA, De Bruyne E, Vanderkerken K, Overgaard MT and Nyegaard M: Abnormal IGF-binding protein profile in the bone marrow of multiple myeloma patients. PLoS One. 11:e01542562016. View Article : Google Scholar : PubMed/NCBI
92	Jelinek DF, Witzig TE and Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol. 159:487–496. 1997.PubMed/NCBI
93	Georgii-Hemming P, Wiklund HJ, Ljunggren O and Nilsson K: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 88:2250–2258. 1996.PubMed/NCBI
94	Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, et al: Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: Therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 95:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
95	Chiron D, Maiga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, et al: Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J. 3:e1202013. View Article : Google Scholar : PubMed/NCBI
96	Huang EW, Xue SJ, Li XY, Xu SW, Cheng JD, Zheng JX, Shi H, Lv GL, Li ZG, Li Y, et al: EEN regulates the proliferation and survival of multiple myeloma cells by potentiating IGF-1 secretion. Biochem Biophys Res Commun. 447:271–277. 2014. View Article : Google Scholar : PubMed/NCBI
97	Vishwamitra D, George SK, Shi P, Kaseb AO and Amin HM: Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 8:1814–1844. 2017. View Article : Google Scholar : PubMed/NCBI
98	Ge NL and Rudikoff S: Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 96:2856–2861. 2000.PubMed/NCBI
99	Bieghs L, Johnsen HE, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover CA, Vanderkerken K and De Bruyne E: The insulin-like growth factor system in multiple myeloma: Diagnostic and therapeutic potential. Oncotarget. 7:48732–48752. 2016. View Article : Google Scholar : PubMed/NCBI
100	Vanderkerken K, Asosingh K, Braet F, Van Riet I and Van Camp B: Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood. 93:235–241. 1999.PubMed/NCBI
101	Asosingh K, Günthert U, Bakkus MH, De Raeve H, Goes E, Van Riet I, Van Camp B and Vanderkerken K: In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res. 60:3096–3104. 2000.PubMed/NCBI
102	Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP and Anderson KC: Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 3:1017–1022. 1997.PubMed/NCBI
103	Podar K and Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood. 105:1383–1395. 2005. View Article : Google Scholar : PubMed/NCBI
104	Andersen NF, Vogel U, Klausen TW, Gimsing P, Gregersen H, Abildgaard N and Vangsted AJ: Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer. 131:E636–E642. 2012. View Article : Google Scholar : PubMed/NCBI
105	Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI
106	Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 17:1359–1370. 2011. View Article : Google Scholar : PubMed/NCBI
107	Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B and Vanderkerken K: Angiogenic switch during 5T2MM murine myeloma tumorigenesis: Role of CD45 heterogeneity. Blood. 103:3131–3137. 2004. View Article : Google Scholar : PubMed/NCBI
108	Bhutani M, Turkbey B, Tan E, Kemp TJ, Pinto LA, Berg AR, Korde N, Minter AR, Weiss BM, Mena E, et al: Bone marrow angiogenesis in myeloma and its precursor disease: A prospective clinical trial. Leukemia. 28:413–416. 2014. View Article : Google Scholar : PubMed/NCBI
109	Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, et al: Induction of angiogenesis by normal and malignant plasma cells. Blood. 114:128–143. 2009. View Article : Google Scholar : PubMed/NCBI
110	Taylor RM, Kashima TG, Knowles HJ and Athanasou NA: VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: Implications for giant cell tumour pathobiology. Lab Invest. 92:1398–1406. 2012. View Article : Google Scholar : PubMed/NCBI
111	Terpos E, Christoulas D, Gavriatopoulou M and Dimopoulos MA: Mechanisms of bone destruction in multiple myeloma. Eur J Cancer Care (Engl). 26:2017. View Article : Google Scholar : PubMed/NCBI
112	Neviani P and Fabbri M: Exosomic microRNAs in the tumor microenvironment. Front Med (Lausanne). 2:472015.PubMed/NCBI
113	Wang X, Lu H, Li T, Yu L, Liu G, Peng X and Zhao J: Krüppel-like factor 8 promotes tumorigenic mammary stem cell induction by targeting miR-146a. Am J Cancer Res. 3:356–373. 2013.PubMed/NCBI
114	Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G and Alessandro R: Exosomes as intercellular signaling organelles involved in health and disease: Basic science and clinical applications. Int J Mol Sci. 14:5338–5366. 2013. View Article : Google Scholar : PubMed/NCBI
115	Raimondo S, Corrado C, Raimondi L, De Leo G and Alessandro R: Role of extracellular vesicles in hematological malignancies. Biomed Res Int. 2015:8216132015. View Article : Google Scholar : PubMed/NCBI
116	Zijlstra A and Di Vizio D: Size matters in nanoscale communication. Nat Cell Biol. 20:228–230. 2018. View Article : Google Scholar : PubMed/NCBI
117	Amodio N, Di Martino MT, Neri A, Tagliaferri P and Tassone P: Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 13 (Suppl 1):S125–S137. 2013. View Article : Google Scholar : PubMed/NCBI
118	Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med. 4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
119	De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E and Van Riet I: Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett. 377:17–24. 2016. View Article : Google Scholar : PubMed/NCBI
120	Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR and Wajapeyee N: miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife. 3:e014602014. View Article : Google Scholar : PubMed/NCBI
121	Raimondi L, De Luca A, Amodio N, Manno M, Raccosta S, Taverna S, Bellavia D, Naselli F, Fontana S, Schillaci O, et al: Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget. 6:13772–13789. 2015. View Article : Google Scholar : PubMed/NCBI
122	Raimondo S, Saieva L, Vicario E, Pucci M, Toscani D, Manno M, Raccosta S, Giuliani N and Alessandro R: Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. J Hematol Oncol. 12:22019. View Article : Google Scholar : PubMed/NCBI
123	Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, Heusschen R, De Raeve H, Schots R, Vanderkerken K, et al: Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 8:1052018. View Article : Google Scholar : PubMed/NCBI
124	Kocemba KA, van Andel H, de Haan-Kramer A, Mahtouk K, Versteeg R, Kersten MJ, Spaargaren M and Pals ST: The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis. Leukemia. 27:1729–1737. 2013. View Article : Google Scholar : PubMed/NCBI
125	Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K and Ohyashiki JH: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124:3748–3757. 2014. View Article : Google Scholar : PubMed/NCBI
126	Lai RC, Chen TS and Lim SK: Mesenchymal stem cell exosome: A novel stem cell-based therapy for cardiovascular disease. Regen Med. 6:481–492. 2011. View Article : Google Scholar : PubMed/NCBI
127	Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, Capelli C, Introna M, Remuzzi G and Benigni A: Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 22:772–780. 2013. View Article : Google Scholar : PubMed/NCBI
128	Chi Y, Yin X, Sun K, Feng S, Liu J, Chen D, Guo C and Wu Z: Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. J Control Release. 261:113–125. 2017. View Article : Google Scholar : PubMed/NCBI
129	Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, Inoue Y, Moore DJ, Nelli E, Dennie T and Bensinger WI: A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. Blood Cancer J. 6:e4222016. View Article : Google Scholar : PubMed/NCBI
130	Umezu T, Imanishi S, Azuma K, Kobayashi C, Yoshizawa S, Ohyashiki K and Ohyashiki JH: Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. Blood Adv. 1:812–823. 2017. View Article : Google Scholar : PubMed/NCBI
131	Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N and Anderson KC: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 101:1530–1534. 2003. View Article : Google Scholar : PubMed/NCBI
132	Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA and Anderson KC: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 111:1654–1664. 2008. View Article : Google Scholar : PubMed/NCBI